Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/50679
Type
ArticleCopyright
Open access
Collections
Metadata
Show full item record63
CITATIONS
63
Total citations
36
Recent citations
24
Field Citation Ratio
2.38
Relative Citation Ratio
SARS-COV-2 VARIANT OF CONCERN P.1 (GAMMA) INFECTION IN YOUNG AND MIDDLE-AGED PATIENTS ADMITTED TO THE INTENSIVE CARE UNITS OF A SINGLE HOSPITAL IN SALVADOR, NORTHEAST BRAZIL, FEBRUARY 2021
https://www.arca.fiocruz.br/handle/icict/48692
Author
Nonaka, Carolina Kymie Vasques
Gräf, Tiago
Barcia, Camila Araújo de Lorenzo
Costa, Vanessa Ferreira
Oliveira, Janderson Lopes de
Passos, Rogério da Hora
Bastos, Iasmin Nogueira
Santana, Maria Clara Brito de
Santos, Ian Marinho
Sousa, Karoline Almeida Felix de
Weber, Thamires Gomes Lopes
Siqueira, Isadora Cristina de
Rocha, Clarissa Araújo Gurgel
Mendes, Ana Verena Almeida
Souza, Bruno Solano de Freitas
Gräf, Tiago
Barcia, Camila Araújo de Lorenzo
Costa, Vanessa Ferreira
Oliveira, Janderson Lopes de
Passos, Rogério da Hora
Bastos, Iasmin Nogueira
Santana, Maria Clara Brito de
Santos, Ian Marinho
Sousa, Karoline Almeida Felix de
Weber, Thamires Gomes Lopes
Siqueira, Isadora Cristina de
Rocha, Clarissa Araújo Gurgel
Mendes, Ana Verena Almeida
Souza, Bruno Solano de Freitas
Affilliation
São Rafael Hospital. Center for Biotechnology and Cell Therapy. Salvador, BA, Brazil / D'Or Institute for Research and Education (IDOR). Salvador, BA, Brazil.
Oswaldo Cruz Foundation. Gonçalo Moniz Institute. Salvador, BA, Brazil.
São Rafael Hospital. Department of Infectology. Salvador, BA, Brazil.
São Rafael Hospital. Department of Infectology. Salvador, BA, Brazil.
São Rafael Hospital. Department of Infectology. Salvador, BA, Brazil.
São Rafael Hospital. Department of Infectology. Salvador, BA, Brazil.
Oswaldo Cruz Foundation. Gonçalo Moniz Institute. Salvador, BA, Brazil.
Oswaldo Cruz Foundation. Gonçalo Moniz Institute. Salvador, BA, Brazil.
São Rafael Hospital. Center for Biotechnology and Cell Therapy. Salvador, BA, Brazil / Oswaldo Cruz Foundation. Gonçalo Moniz Institute. Salvador, BA, Brazil.
Oswaldo Cruz Foundation. Gonçalo Moniz Institute. Salvador, BA, Brazil.
São Rafael Hospital. Clinical Laboratory. Salvador, BA, Brazil.
Oswaldo Cruz Foundation. Gonçalo Moniz Institute. Salvador, BA, Brazil.
São Rafael Hospital. Center for Biotechnology and Cell Therapy. Salvador, BA, Brazil / Oswaldo Cruz Foundation. Gonçalo Moniz Institute. Salvador, BA, Brazil.
São Rafael Hospital. Department of Infectology. Salvador, BA, Brazil.
São Rafael Hospital. Center for Biotechnology and Cell Therapy. Salvador, BA, Brazil / Oswaldo Cruz Foundation. Gonçalo Moniz Institute. Salvador, BA, Brazil.
Oswaldo Cruz Foundation. Gonçalo Moniz Institute. Salvador, BA, Brazil.
São Rafael Hospital. Department of Infectology. Salvador, BA, Brazil.
São Rafael Hospital. Department of Infectology. Salvador, BA, Brazil.
São Rafael Hospital. Department of Infectology. Salvador, BA, Brazil.
São Rafael Hospital. Department of Infectology. Salvador, BA, Brazil.
Oswaldo Cruz Foundation. Gonçalo Moniz Institute. Salvador, BA, Brazil.
Oswaldo Cruz Foundation. Gonçalo Moniz Institute. Salvador, BA, Brazil.
São Rafael Hospital. Center for Biotechnology and Cell Therapy. Salvador, BA, Brazil / Oswaldo Cruz Foundation. Gonçalo Moniz Institute. Salvador, BA, Brazil.
Oswaldo Cruz Foundation. Gonçalo Moniz Institute. Salvador, BA, Brazil.
São Rafael Hospital. Clinical Laboratory. Salvador, BA, Brazil.
Oswaldo Cruz Foundation. Gonçalo Moniz Institute. Salvador, BA, Brazil.
São Rafael Hospital. Center for Biotechnology and Cell Therapy. Salvador, BA, Brazil / Oswaldo Cruz Foundation. Gonçalo Moniz Institute. Salvador, BA, Brazil.
São Rafael Hospital. Department of Infectology. Salvador, BA, Brazil.
São Rafael Hospital. Center for Biotechnology and Cell Therapy. Salvador, BA, Brazil / Oswaldo Cruz Foundation. Gonçalo Moniz Institute. Salvador, BA, Brazil.
Abstract
Objectives: To evaluate changes in the characteristics of patients with coronavirus disease 2019 (COVID-19) after the emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concern (VOC) P.1 (Gamma), by comparing the clinical, demographic, and laboratory profiles of patients hospitalized during the first (May to July 2020) and second (December 2020 to February 2021) pandemic waves. Methods: Data were collected from the records of COVID-19 patients (n = 4164) admitted to a single hospital in Salvador, Northeast Brazil. SARS-CoV-2 genome sequencing was performed on nasopharyngeal swab samples from 12 patients aged <60 years admitted to the intensive care unit (ICU) in February 2021. Results: Between June 2020 and February 2021, the median age of patients admitted to the ICU decreased from 66 to 58 years (P < 0.05). This was accompanied by an increased proportion of patients without comorbidities (15.32% vs 32.20%, P < 0.0001). A significant reduction in the cycle threshold values of SARS-CoV-2 RT-PCR tests was observed in the second wave (P < 0.0001). Sequencing analysis detected lineage Gamma in all 12 ICU patients sampled in February 2021. Conclusions: The results of this study demonstrated an increased proportion of younger adults without comorbidities with severe disease during the second COVID-19 wave, shortly after the confirmation of local Gamma circulation.
Share